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CASE PRESENTATION: DR. AISHA GHARE
A 4-year-old male was admitted to the pediatric medicine
service after a 5-day history of severe holocephalic headaches and
an episode of emesis the day prior to admission. The headaches
were progressive in severity, occurring in the early morning and
often walking him up from sleep. No seizure activity, focal
deficits, or infectious symptoms were reported by parents. His
past medical history was significant for diagnosis of acute
monocytic leukemia (AML) 1 year previously. Bone marrow
karyotyping and interphase fluorescence in-situ hybridization at
the time of initial presentation revealed AML with 11q23 abnor-
malities at the MLL (mixed lineage leukemia) gene, with t(1:17)
and ins(10;11). He received four cycles of chemotherapy on the
Children’s Oncology Group (COG) protocol AAML1031,1 with
a line infection complicating his third cycle. After his fourth
cycle, he was discharged home. Throughout his initial diagnosis
and up to the time of current presentation – 6 months after his last
chemotherapy cycle – he did not demonstrate any signs or
symptoms of neurologic abnormality and was central nervous
system (CNS)-negative.
His vitals were within normal limits, and a systemic physical
examination was unremarkable. On neurologic exam, there were
no noted cranial-nerve deficits or papilledema. No objective
deficits in power, sensation, and cerebellar testing were elicited,
and no upper motor neuron signs were elicited. Initial bloodwork
showed no abnormalities.
DISCUSSION: DR. ANDRADE
The history provided of a 4-year-old child post-chemotherapy –
thus likely in an immunosuppressive state – presentingwith a clinical
picture of early morning vomiting and headache suggests raised a
process of raised intracranial pressure (ICP). There are no focal signs
indicating a clear localization of the lesion, instead the findings
indicate a progressive and diffuse process. Typically, headache,
vomiting, and gait disturbances are seen in posterior fossa occupying
lesions, whereas supratentorial tumors typically present with focal
seizures, motor, language, or sensory abnormalities.
The differential diagnosis of immunocompromised children
with posterior fossa mass can be divided into three broad
categories: neoplastic, infectious, or vascular.
Regarding vascular etiologies, cerebral venous sinus thrombo-
sis (CVST) is a common complication of children with leukemia,
specifically those who are prothrombotic due to the lymphopro-
liferative disease or those who have received asparaginase as part
of their treatment (e.g. patients with ALL). CVST can present with
nonspecific signs of increased ICP. Usually, venous infarctions are
associated with focal seizures and cortical deficits. Other vascular
complications such as acute ischemic stroke, intracerebral hemor-
rhage, and posterior reversible encephalopathy syndrome are rather
acute and present with sudden onset of focal deficits, rather than
the progressive headaches we see in this case.
The next possibility is an opportunistic infection, which can be
seen in children receiving chemotherapy. The most common ones
include fungal infections such as Aspergillus and Candida. During
chemotherapy-induced neutropenia, colonization with fungi is
considered as a major risk factor for a subsequent fungal infection.
Usually, these patients present with a more severe presentation and
are also associated with systemic aspergillosis. The clinical picture
would include confusion and focal neurological deficits. Multiple
enhancing lesions can be seen on contrast CT and MRI.
Lastly, and most likely differential, is neoplasm. CNS leuke-
mic infiltration can present in one or more of the following
intracranial forms: (1) meningeal disease, as “carcinomatosis
meningitis”; (2) intravascular tumor aggregates throughout the
brain as “carcinomatous encephalitis”; (3) focal solid extrame-
dullary hematopoietic tumors called “chloromas,” also termed
myeloid sarcoma (MS); and (4) leukemic blasts in the cerebro-
spinal fluid (CSF), typically defined as the presence of at least five
leukocytes/μl of CSF, with leukemic blast cells apparent in a
cytocentrifuged sample of cerebrospinal fluid, or the presence of
cranial-nerve palsies.2
Central nervous system myeloid sarcoma (CNS-MS) is a rare
manifestation of AML, chronic myeloid leukemia (CML), and
other myeloproliferative malignancies. Intracranially, MSs are
often contiguous with the meninges and ependyma but can rarely
present intraaxially. When AML manifests as a solid tumor
outside the bone marrow, it can be mistaken with meningioma,
B cell lymphoma and intracranial metastasis. MS can express B
cells antigens and potentially lead to a histologically misdiagno-
sis of CNS lymphoma. Another consideration in this case would
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include primary CNS lymphoma. Given the clinical signs of
raised ICP and a broad differential, I would like to see neuroim-
aging, and if there are no masses that are a contraindication to a
lumbar puncture, then proceed with the latter to assess results of
CSF analysis. A bone marrow analysis would be useful to assess
whether the patient has active disease again.
INVESTIGATIONS: DR. GHARE AND DR. KIWAN
Bone marrow workup showed no morphologic evidence of
marrow involvement with AML.
An unenhanced CT scan demonstrated a hyperdensity in the
right cerebellar hemisphere with surrounding edema and right
cerebellar tonsillar descent resulting in crowding of the foramen
magnum (Figure 1). MRI confirmed a lesion in the right cerebellar
hemisphere, with prominent contrast enhancement, with a linear
focus of enhancement at the margin (Figure 2A). Fluid-attenuated
inversion recovery (FLAIR) sequences showed moderate sur-
rounding edema, crowding of the basal cisterns, and mass effect
on the fourth ventricle (Figure 2B, C). Axial multiplanar gradient
echo sequences showed few punctate foci of susceptibility within
the lesion in keeping with calcification or blood product (not
shown), and diffusion-weighted imaging (DWI) and apparent
diffusion coefficient (ADC) images showed diffusion restriction,
indicating hypercellularity.
Radiological differential diagnosis of the lesion included
chloromas, cerebellar astrocytoma, medulloblastoma, and atypi-
cal teratoid/rhabdoid tumor.
DISCUSSION: DR. ANDRADE
The bone marrow findings show that the patient does not have
active AML; however, this would not preclude development of
MS, as these can manifest following clinical remission. Given the
Figure 1: Axial noncontrast CT scan reveals a hyperdense mass in the right cerebellar hemisphere with
moderate surrounding vasogenic edema causing effacement of the fourth ventricle (A) and right cerebellar
tonsillar descent resulting in crowding of the foramen magnum (B).
Figure 2: MRI confirmed a lesion in the right cerebellar hemisphere, with prominent contrast enhancement, with a linear
focus of enhancement at the margin (A). FLAIR sequences showed moderate surrounding edema, crowding of the basal
cisterns, and mass effect on the fourth ventricle (B). Axial multiplanar gradient echo sequences showed few punctate foci of
susceptibility within the lesion in keeping with calcification or blood product (not shown) and DWI (C) and ADC images
showed diffusion restriction, indicating hypercellularity (not shown).
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imaging findings, and interpretation from neuroradiology collea-
gues, I suspect that this lesion may be an MS. At this point, I
would consult my neurosurgical colleagues on the possibility of a
biopsy to provide a tissue diagnosis, and/or full resection of the
lesion.
NEUROSURGERY: DR. RANGER
The Pediatric Neurosurgery team was approached by the
Pediatric Oncology team for consideration of a biopsy, and
possibly a resection. Empiric treatment of the lesion as chloroma
was felt to be inappropriate; if the tumor was unrelated to his
leukemia, it would likely need to be fully resected to confer the
best survival advantage.
After discussion among the Oncology Team, Neurosurgery
and Neuropathology, it was felt that the most prudent
course would be to pursue a biopsy and send specimens
intraoperatively for frozen sectioning for a preliminary tissue
diagnosis and flow cytometry and base further resection on the
results of the biopsy.
The patient underwent a suboccipital craniotomy, and after
exposing through the dura and normal cerebellar tissue, we
landed on the mass. It had a rather firm capsule and had a pale
appearance overall with beige coloration and only a mild degree
of vascularity. Several specimens were submitted for intraopera-
tive consultation to neuropathology, with additional sections for
permanent sections and flow cytometry.
PATHOLOGY: DR. LANGDON
Staff neuropathologist, Dr. Hammond, examined the intrao-
perative sample. Smear preparations and frozen sections
revealed a small blue cell tumor, favoring hematopoietic lineage
(Figure 3A).
On flow cytometry, a population of lesional cells representing
approximately 81% of the total were positive for CD117 (dim),
CD33 (bright), CD64, CD36 (dim), CD4 (dim), HLA-DR, and
CD38 and negative for CD34, CD19, CD10, CD13, CD16, CD14
(MY4 and Mo2), CD7, CD3, and CD5. These features were
consistent with extramedullary involvement by AML.
On routine stains, the specimen demonstrated a densely
cellular mononuclear neoplasm (Figure 3B). Neoplastic cells
possessed large nuclei with variably prominent nucleoli and
folds. Auer rods were noted in select cells. The brain:tumor
interface was relatively well defined (Figure 3C) as shown with
glial fibrillary acidic protein (GFAP) staining, but with sparse
infiltrates of single cells into adjacent parenchyma. Immunohis-
tochemistry (IHC) demonstrated abundant expression of CD4
(Figure 3D), CD163, and CD68 (Figure 3E). Selective and lighter
expression of CD117 and myeloperoxidase (MPO) (Figure 3F)
was identified in a small minority of cells. CD34 highlights the
background vasculature, and TdT was not expressed (not shown).
The final diagnosis was chloroma.
PATIENT FOLLOW-UP: DR. GHARE
When the preliminary interpretation was consistent with a
chloroma, the neurosurgical team proceeded with closure of the
dura and craniotomy, not resecting any further tissue. The patient
recovered well from surgery, without postoperative complica-
tions. Once the diagnosis was confirmed, the patient was started
on chemotherapy with high-dose fludarabine and cytarabine, for
three cycles. His first postoperative MRI one month later showed
a small area of poorly defined enhancement in the right cerebellar
hemisphere, improved from his initial MRI. However, a repeat
scan two month postoperatively demonstrated slight increase in
the size of the enhancing nodule and there was concern of
recurrence. The patient was given 2000 cGy in 10 fractions.
Both a peripheral smear and bone marrow analysis demonstrated
leukemic blasts, and he was started on a salvage regimen of
Ara-C/idarubicin and gemtuzumab. Unfortunately, he went on to
have an opportunistic pneumonia, with associated pleural
effusion and bacteremia. He was started on broad spectrum
antibiotics but continued to remain febrile and had decreasing
level of consciousness. A day later, he had further deterioration,
with stiffening and posturing, and dilated and unreactive pupils. It
was felt that he likely had an acute CNS event; family did want
any investigations or aggressive intervention and wanted to focus
on comfort care. The patient died a few hours later and family
declined an autopsy.
TOPIC REVIEW: DR. GHARE
MS is a rare solid tumor made of myeloblasts or immature
myeloid cells in an extramedullary site or in bone.3 It was first
described by Burns in 1811 as “chloroma” from the Greek word
“chloros” (green), as these tumors often have a green tint due to
the presence of MPO. MS has also been termed extramedullary
myeloid tumor or granulocytic sarcoma. Diagnosis often
precedes, coincides, or follows hematologic neoplasms (HNs)
such as acute myeloid leukemia, chronic myeloproliferative
neoplasms, chronic myelogenous leukemia, polycythemia vera,
myelofibrosis, essential thrombocythemia, and myelodysplastic
syndrome. AML is the most common associated malignancy,
accounting for 46.3% of cases.4 In 2003, Audouin et al.5
described four different patterns of MS development in patients
with AML: (1) they may develop during the active phase of
leukemia; (2) they may develop concurrently with known chronic
myeloproliferative disorders; (3) they may manifest as a relapse
after months or years of clinical remission of AML, especially
after bone marrow transplantation; and (4) they may precede the
AML diagnosis to be detected in previously healthy patients who
have a normal peripheral blood cell count and who have no blast
infiltration of the bone marrow; 80–87% of these patients will go
on to develop AML within 10 months.6,7 MS occurs in 1.4–9% of
AML cases, and in 3–8% of all patients with HNs.8
MS typically presents in the orbit, skin, soft tissue, bone,
lymph nodes, and the gastrointestinal tract.8 CNS-MSs are rare,
occurring in 0.3–6% of patients with HNs, and are more prevalent
in males than females, likely reflecting the gender distribution of
myeloid leukemia.6,7 CNS-MS is often contiguous with the
meninges and ependyma, but can rarely invade the brain paren-
chyma and thus may appear as an intraaxial mass. MS is more
common in the spinal cord (54%) than in the brain (40%), and
rarely in both (6%); when it occurs in the spinal cord, tumors are
usually epidural and cause cord compression.8 In the brain, MS
frequently involves the parenchyma (43–54%), followed by dura
(41%).2,8 Though deemed rare, several large treatment trials and
case series have been published in the literature reporting CNS-
MS.9–17 In the Children’s Cancer Group (CCG) protocols for
intensive-timing chemotherapy treatment for AML,10 the authors
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reported that of the 1459 patients, 19 (1%) had CNS-MS, while
the NOPHO (Nordic Society of Pediatric Hematology and On-
cology)-AML 2004 trial of 315 patients found 22 (7%) had CNS
disease but only 2 had MS in the dural/epidural space.9
The pathogenesis of CNS infiltration is unclear; it is hypothe-
sized that leukemic cell infiltrates are capable of migration from
the bone marrow of the periosteum to the dura, into the underly-
ing brain parenchyma once there is disruption of the pial–glial
barrier.18 However, this theory does not explain the development
of MS lesions deep in the brain parenchyma.
Radiologic features of CNS-MS are nonspecific: on CT,
lesions typically present as anisodense or hyperdense mass,
with marked homogenous contrast enhancement. MRI reveals
a hypo to isointense on T1- and T2WI with homogenous
enhancement following gadolinium administration.2,16 Using
the NOPHO-AML registry, Ranta et al. evaluated the neuro-
imaging findings in 22 of 34 children with AML and CNS
involvement at diagnosis. They found that five had CNS
involvement by imaging, two had solid contrast enhancing
intracranial tumors, one had an orbital tumor with intracranial
Figure 3: Smear preparation and frozen demonstrated small blue cell tumor, favoring lymphoid tissue (A). On routine stains,
the specimen demonstrated a densely cellular mononuclear neoplasm, with variably prominent nucleoli and folds (B). The
brain:tumor interface was relatively defined (C) as shown with GFAP staining, but with sparse infiltrates of single cells into
adjacent parenchyma. Immunohistochemistry demonstrated abundant expression of CD4 (D), CD163, and CD68 (E).
Selective and lighter expression of CD117 and myeloperoxidase (F) was identified in a small minority of cells. Diagnosis was
consistent with myeloid sarcoma.
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contrast enhancement, and two had spinal tumors.19 Rare
parenchymal cases have shown peripheral ring enhancement.
Thus, CNS-MS may mimic CNS lymphoma, glioblastoma, and
if dura-based, meningioma and schwannoma. In the spine,
CNS-MS may show nerve root thickening, mimicking nerve
sheath tumors.
Definitive diagnosis depends on pathology, immunohistochem-
istry (IHC), and flow cytometry. Routine staining will show a
characteristic Indian file pattern, and the MIB-1 monoclonal anti-
body index is usually high; the predominant cell type will determine
classification into granulocytic, monoblastic, and myelomonocytic.
An appropriate IHC panel would include CD43, CD34, lysozyme,
MPO, CD68 (or CD163), CD117, CD3, and CD20.
CNS-MS is typically managed through a combination of local
surgical resection, chemotherapy, and radiation; however, the
utility and safety of surgical resection is still controversial. Some
advocate surgical resection only if the MS is spinal and causing
cord compression, especially as complete surgical resection is
difficult due to the extensive infiltration of MS into surrounding
tissues.16 There are no established guidelines for the management
of CNS-MS, given its rare occurrence, however, a review of 45
cases of CNS-MS by Struhal et al., looking at systemic/intrathe-
cal chemotherapy, radiation, and surgery, found that there was no
superior modality among combination of treatment options avail-
able, but suggested that systemic chemotherapy and irradiation
might have a slight advantage with respect to 1-year survival.20
Complete resolution of CNS-MS following chemotherapy or
radiation was reported in 24 of 125 reviewed cases by Olar
et al., with overall survival after CNS-MS diagnosis found to be a
few days to 114 months in 94 patients with available data.8
The effect of MS on prognosis is unclear.21 In an AML
registry of 240 pediatric patients, Kobayashi et al. found that
the complete remission rate of patients with extramedullary
manifestation of leukemia (EML) was lower than for other
patients and that patients with CNS-MS who had a WBC
>100 × 109/L had lower event fee survival (23.8%) than those
with no CNS-MS and/or WBC <100 × 109/L (62.4%), suggest-
ing that the combination of both is a risk factor for relapse.22 In
the NOPHO registry, the presence of EML was significantly
associated with higher risk of death during induction therapy than
non-EML patients (8% vs. 1%, p= 0.002), with four of the six
patients (including two with CNS involvement at diagnosis)
dying as a result of cerebral bleeding or infarction. EML patients
also had a significantly lower 5-year overall survival (OS) of 64%
compared with non-EML patients (73%) and the former.9 Con-
versely, the 2012 CCG trials showed that overall survival and
event-free survival (EFS) were significantly higher in orbital MS
and CNS MS patients compared with non-CNS MS and non-MS
patients.10 There was also no significant difference in the bone
marrow or isolated CNS relapse rate between the four groups of
patients. Interestingly, analysis of children with AML from two
consecutive COG Phase III trials by the CCG in 2017 demon-
strated that increasing degrees of CNS involvement (i.e., CNS3
where there are >5 WBCs with blasts in cytospin or presence of
chloroma) despite receiving intensified intrathecal therapy) is
significantly associated with worse overall survival and disease-
free survival.23
A multicenter French trial, conducted between 2005 and 2011,
which analyzed the outcomes of children with AML and CNS
involvement (CNS +) treated with the ELAM02 protocol.17
Treatment involved induction chemotherapy with cytarabine and
mitoxantrone, followed by first consolidation with high-dose
cytarabine and amsacrine and then either a bone marrow
transplant or two additional courses of chemotherapy. They
found no significant difference in the OS between patients with
CNS + (76%, 95% CI 63–84%) and without (71%, 95%
CI 66–75%). Similarly, the EFS rates were also not significantly
different between the CNS + (57%, 95% CI 44–67%) and
CNS− group (52%, 95% CI 46–57%). There was no difference
between the clinical remission rates or the percentage of patients
who underwent bone marrow transplant after clinical remission
between the two arms. Patients with CNS involvement had a
significantly higher incidence of combined bone marrow and
CNS relapse (26% vs. 10%); however, the CNS+ group had a
lower rate of relapse after bone marrow transplant (5%) vs. the
CNS− group (27%).
CONCLUSION
CNS infiltration by immature myeloid cells or myeloblasts is
quite rare and can sometimes precede the diagnosis of a systemic
hematologic malignancy. Diagnosis rests on a combination of
IHC and histopathology of biopsied tissue. Surgical resection is
controversial, especially given the efficacy of chemotherapy and
radiation, and prognosis remains unclear. As with all uncommon
and rare clinical entities, further investigation is warranted to
determine prognosis and optimal management of CNS MSs.
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